SCYNEXIS Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal Infections

Core Insights - SCYNEXIS, Inc. has completed the dosing of the first cohort in its Phase 1 trial for SCY-247, a second-generation antifungal aimed at treating severe invasive fungal infections [1][2] - The company emphasizes the urgent need for new antifungal therapies due to rising drug resistance and high mortality rates associated with invasive fungal diseases [2] Company Overview - SCYNEXIS is a biotechnology firm focused on developing innovative medicines to combat difficult-to-treat infections, particularly those that are increasingly drug-resistant [4] - The company’s antifungal platform, known as "fungerps," includes Ibrexafungerp, which has received FDA approval for vulvovaginal candidiasis and is under investigation for invasive fungal infections [4] Product Development - SCY-247 is a novel antifungal compound from a new class of glucan synthase inhibitors, showing broad-spectrum antifungal activity against multidrug-resistant pathogens [3] - The Phase 1 trial for SCY-247 involves approximately 100 healthy subjects, focusing on safety, tolerability, and pharmacokinetics [2][3] - SCYNEXIS anticipates potential FDA designations for SCY-247, including Qualified Infectious Disease Product (QIDP) and Fast Track status for both oral and IV formulations [3]